Coultreon Biopharma
Transforming lives with groundbreaking treatments
Coultreon Biopharma is a biotech company in Leuven, United States, founded in 2025. It has raised $125.0M across 1 round, most recently a $125.0M Series A in April 2026.
- Headquarters
- Leuven
- Employees
- 11–50
- Founded
- 2025
- Business Model
- B2B
- Website
- coultreon.com
- Total Funding
- $125.0M
- Last Round
- $125.0M Series AApr 2026
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round and 5 investors for this company. to use credits for reveals, or explore the API.
About
Coultreon Biopharma (formerly Onco3R Therapeutics) is a Leuven, Belgium-based clinical-stage biotech founded in 2025 developing precision medicines for autoimmune and inflammatory diseases. Its lead asset COL-5671 is a selective SIK3 inhibitor that completed Phase 1 with favorable safety and pharmacokinetic data, targeting ulcerative colitis and other immune-mediated conditions with a once-daily oral therapy.
Funding History
Apr 2026
Investors
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
- Cloud/Infrastructure ×1
- Frontend ×1
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Companies in related industries
China's leading blood products manufacturer

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...

Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/coultreon-biopharma"><img src="https://indexed.vc/api/badge/company/coultreon-biopharma" alt="Coultreon Biopharma on Indexed.vc" width="260" height="76" /></a>
